Addex Therapeutics Ltd - ADR

NASDAQ:ADXN  
0.78
-0.02 (-2.49%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)4.92M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.23 Million
Adjusted EPS-$0.09
See more estimates
10-Day MA$0.83
50-Day MA$1.12
200-Day MA$3.62
See more pivots

Addex Therapeutics Ltd - ADR Stock, NASDAQ:ADXN

9, Chemin des Aulx, Plan-les-Ouates, Geneva, Geneve (Geneva) 1202
Switzerland
Phone: +41.22.884.15.55
Number of Employees: 28

Description

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.